Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

NCT02581865 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette Syndrome

Interventions

DRUG: NBI-98854
DRUG: Placebo

Sponsor

Neurocrine Biosciences